By way of example, in melanoma, IFI30 could boost the processing and presentation of tumor antigens, TRP1 and TRP2, resulting in enhanced anti-tumor T-cell responses and ultimately higher patient survival (40–42). This evidence concerns the gene IFI30 and melanoma.